|Bid||0.00 x 900|
|Ask||92.40 x 1400|
|Day's Range||90.91 - 92.48|
|52 Week Range||78.74 - 96.06|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.92|
|Expense Ratio (net)||0.14%|
Wells Fargo's Christopher Harvey says don't worry, the rally is on the way. Is value back in vogue? With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Steve Grasso and Guy Adami.
Julian Emanuel, BTIG, says investors shouldn't panic here, and discusses whether there's more market volatility ahead. With CNBC's Joe Kernen and the Fast Money traders, Pete Najarian, Steve Grasso, Brian Kelly and Tim Seymour.
John Sculley, RX Advance chairman and former CEO of Apple, joins 'Squawk Alley' to discuss how the healthcare industry is going to change following the midterm elections.
Ana Gupte, Leerink Partners senior analyst and managing director of healthcare services, discusses the outlook for health care following the midterm elections creating a divided Congress.
Stocks soared as the results of the US midterm elections panned out as anticipated, with Democrats winning back control of the House of Representatives and Republicans retaining the Senate.
PNC's Jeffrey Mills on the biggest risks to the market. With CNBC's Bob Pisani and Melissa Lee, and the Fast Money traders, Tim Seymour, Karen Finerman, Steve Grasso and Guy Adami.
U.S. stocks snap a 3-day winning streak to wrap up a volatile trading week on Wall Street. Jared Blikre breaks down all the live market action from the floor of the New York Stock Exchange.
Trump says the GOP will protect pre-existing conditions, but their actions say otherwise. Rick Newman on what's going on.
With the mid-term election dust settling, ETF investors can now consider the state of sector investing and look to opportunities that may lie ahead. On the recent webcast (available On Demand for CE Credit), ...
ETF investors who want to gain targeted exposure in the markets today should consider traditional and new economy sector-based strategies that could help align portfolios with market events, harness macro ...
Shares of Cardinal Health Inc. rallied 2.9% in premarket trade Thursday after the healthcare services company reported fiscal first-quarter profit and revenue that rose above expectations, boosted by strength in its pharmaceuticals business. Net income rose to $593 million, or $1.94 a share, from $115 million, or 36 cents a share, in the same period a year ago, with the naviHealth divestiture resulting in a gain of $503 million. Excluding non-recurring items, adjusted earnings per share came to $1.29, above the FactSet consensus of $1.08. Revenue increased 8% to $35.2 billion, beating the FactSet consensus of $33.7 billion. Pharmaceutical segment revenue grew 9% to $31.4 billion, well above the FactSet consensus of $29.8 billion. The company affirmed its 2019 adjusted EPS outlook of $4.90 to $5.15, which surrounds the FactSet consensus of $4.99. The stock has rallied 9.6% over the past three months through Wednesday, while the SPDR Health Care Select Sector ETF has gained 3.4% and the S&P 500 has slipped 1.5%.
Even as the Democrats retook control of the House of Representatives and the Republicans maintained majority in the Senate, healthcare ETFs were also big winners following the 2018 Midterm Election results. ...
Shares of Humana Inc. were indicated up about 1.5% in prmarket trade Wednesday, after the health care company reported third-quarter earnings that rose above expectations and raised its full-year outlook, helped by strength in its individual Medicare Advantage offerings. Net income rose to $901 million, or $4.65 a share, from $799 million, or $3.44 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share increased to $4.58 from $3.39, and beat the FactSet consensus of $4.27. The health care company raised its 2018 guidance for adjusted EPS to "approximately" $14.40 from approximately $14.15. Total revenue rose 7% to $14.21 billion, above the FactSet consensus of $13.92 billion, as premiums increased 5.8% to $13.71 billion to top expectations of $13.45 billion. The stock has gained 3.1% over the past three months, while the SPDR Health Care Select Sector ETF has edged up 0.6% and the S&P 500 has lost 3.6%. (This updates a previous item to include revenue, which was provided in an SEC filing that became available after the press release.)
Shares of AmerisourceBergen Corp. tumbled 9.1% in morning trade Tuesday, after the drug company reported fiscal fourth-quarter earnings and revenue that just topped expectations but provided a downbeat profit outlook, citing a "potential sizable headwind" for its PharMEDium business. The company also disclosed in filing with the Securities and Exchange Commission that production at PharMEDium's facilities remains suspended, while Leerink analyst David Larsen said commercial operations were previously expected to begin in September, as the company waited for feedback from the Food and Drug Administration. Earlier Tuesday, the company reported fourth-quarter net income of $233.3 million, or $1.07 a share, compared with a loss of $344.6 million, or $1.58 a share, in the same period a year ago. Adjusted earnings per share came to $1.45, above the FactSet consensus of $1.44, but the fiscal 2019 adjusted EPS outlook of $6.65 to $6.95 was below expectations of $7.11. The stock has lost 2.0% over the past three months, while the SPDR Health Care Select Sector ETF has gained 0.3% and the S&P 500 has lost 3.6%.
The Health Care Select Sector SPDR (XLV) is up more than 2% over the past week, but the largest healthcare exchange traded fund and rival funds will likely be tested by the results of today's midterm elections. Currently, most political prognosticators are forecasting the Democrats gaining control of the House while the Republicans are expected to maintain control of the Senate. “Many investors see health-care investments as a defensive play because demand for health products and services tends to remain stable throughout various phases of the business cycle,” reports Tanzeel Akhtar for the Wall Street Journal.
Eli Lilly & Co. reported Tuesday third-quarter earnings and revenue that topped expectations and raised its full-year guidance. The stock was still inactive in premarket trade. Net income rose to $1.15 billion, or $1.12 a share, from $555.6 million, or 53 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $1.39, above the FactSet consensus of $1.37. Revenue rose 7% to $6.06 billion, just beating the FactSet consensus of $6.05 billion. Among the drug maker's top sellers, Humalog revenue fell 5% to $664.6 million, missing the FactSet consensus of $707.4 million, and Trulicity revenue jumped 55% to $816.2 million, just shy of expectations of $816.6 million. Animal health revenue grew 4% go $772.7 million, above the FactSet consensus of $760.1 million. For 2018, the company raised its adjusted EPS outlook to $5.55 to $5.60 from $5.40 to $5.50 and revised up its revenue guidance to $24.3 billion to $24.5 billion from $24.0 billion to $24.5 billion. The stock has rallied 8.0% over the past three months, while the SPDR Health Care Select Sector ETF has inched up 0.1% and the Dow Jones Industrial Average has eased 0.2%.
Americans and investors have a lot riding on Tuesday’s midterm elections, but the health care industry in particular is hanging in the balance. On Monday, Height Capital Markets named four themes in the ...
The US jobs report for October was released on November 2. The strong job additions came after lackluster September additions of 134,000, which were further revised downward to 118,000 in October. The unemployment rate remained steady at 3.7% in October.
The non-farm payrolls for September in the US (IVV) (QQQ) were 134,000, which was weaker than economists’ expectation of 180,000 job additions. The bright point was that August’s job additions were revised upwards by 69,000. After last month’s disappointing job additions, partly due to Hurricane Florence, analysts are expecting payrolls to bounce back in October.
Investing in the healthcare sector is often regarded as a hedge from regular market forces due to the underlying nature of the work. Investors looking for an ETF to track the performance of the healthcare sector generally turn to the Health Care Select Sector SPDR Fund.
Merck’s revenues grew 5% YoY (year-over-year) to $10.8 billion in the third quarter. Its net revenues were $31.3 billion in the first nine months of the year compared to $29.7 billion in the first nine months of 2017, reflecting a ~5% YoY growth.